Akebia Therapeutics Files 8-K
Ticker: AKBA · Form: 8-K · Filed: Mar 14, 2024 · CIK: 1517022
| Field | Detail |
|---|---|
| Company | Akebia Therapeutics, Inc. (AKBA) |
| Form Type | 8-K |
| Filed Date | Mar 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, financials
Related Tickers: AKBA
TL;DR
AKBA filed an 8-K, standard procedure, no major news.
AI Summary
Akebia Therapeutics, Inc. filed an 8-K on March 14, 2024, reporting on its results of operations and financial condition, as well as filing financial statements and exhibits. The filing does not appear to contain specific financial figures or operational updates beyond the reporting of these items.
Why It Matters
This filing indicates Akebia Therapeutics is fulfilling its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine filing for a public company and does not appear to contain any new material information that would immediately impact the company's risk profile.
Key Players & Entities
- Akebia Therapeutics, Inc. (company) — Registrant
- March 14, 2024 (date) — Date of Report
- 245 First Street Cambridge, Massachusetts 02142 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Akebia Therapeutics?
The primary purpose is to report on the company's Results of Operations and Financial Condition, and to file Financial Statements and Exhibits.
What is the exact date of this filing?
The filing was made on March 14, 2024.
What is Akebia Therapeutics' principal executive office address?
The principal executive office is located at 245 First Street, Cambridge, Massachusetts 02142.
What is Akebia Therapeutics' IRS Employer Identification Number?
The IRS Employer Identification Number is 20-8756903.
Under which section of the SEC Act is this report filed?
This is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-03-14 16:18:29
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share AKBA The Nasdaq Capital Marke
Filing Documents
- akba-20240314.htm (8-K) — 31KB
- drafpr12312023.htm (EX-99.1) — 89KB
- 0001517022-24-000029.txt ( ) — 268KB
- akba-20240314.xsd (EX-101.SCH) — 2KB
- akba-20240314_def.xml (EX-101.DEF) — 4KB
- akba-20240314_lab.xml (EX-101.LAB) — 24KB
- akba-20240314_pre.xml (EX-101.PRE) — 14KB
- akba-20240314_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 14, 2024, Akebia Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023 and commenting on certain business updates. A copy of the Company's press release containing this information is furnished as Exhibit 99.1 to this Current Report on Form 8-K ("Report") and is incorporated herein by reference. The information in this Report (including Item 2.02 and Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated March 14 , 202 4 , issued by Akebia Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AKEBIA THERAPEUTICS, INC. Date: March 14, 2024 By: /s/ John P. Butler Name: John P. Butler Title: President and Chief Executive Officer